These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26419617)

  • 1. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
    Mirone G; Perna S; Shukla A; Marfe G
    J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
    Aprile G; Macerelli M; Giuliani F
    BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
    Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
    Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
    Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
    Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
    Chen D; Wei L; Yu J; Zhang L
    Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
    Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
    Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of regorafenib and its current and potential future role in cancer therapy.
    Davis SL; Eckhardt SG; Messersmith WA; Jimeno A
    Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
    Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
    J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.
    Camaj P; Primo S; Wang Y; Heinemann V; Zhao Y; Laubender RP; Stintzing S; Giessen-Jung C; Jung A; Gamba S; Bruns CJ; Modest DP
    Future Oncol; 2015; 11(13):1919-29. PubMed ID: 26161928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
    Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
    PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.